Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced two oral presentations on TONMYA, investigated as TNX-102 SL (cyclobenzaprine HCl sublingual tablets), at the 8th International Congress on Controversies in Fibromyalgia held March 9-10, 2026, in Krakow, Poland. The presentations highlighted data from post hoc analyses of the Phase 3 RESILIENT trial and pooled data from the RELIEF and RESILIENT studies, demonstrating rapid pain relief and a favorable benefit-risk profile for TONMYA in adults with fibromyalgia.
The findings revealed statistically significant reductions in pain and a likelihood of clinical benefit nearly four times greater than discontinuation due to adverse events. TONMYA, the first medication approved for fibromyalgia in more than 15 years, was generally well tolerated, with mild and transient oral cavity reactions reported as the most common adverse events. These results underscore the potential of TONMYA to address a significant unmet medical need in the fibromyalgia community.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg) is the company’s recently approved flagship medicine. In addition to fibromyalgia, Tonix is evaluating TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder. The company's CNS portfolio also includes TNX-2900, which is Phase 2 ready for Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for prevention of kidney transplant rejection.
For more information on the full press release, visit https://ibn.fm/hv3Cl. To stay updated on the latest news regarding TNXP, visit the company’s newsroom at https://ibn.fm/TNXP.
